Retracted: Immunoglobulin G4+ B‐cell receptor clones distinguish immunoglobulin G 4‐related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Immunoglobulin G4 (IgG4)‐related disease (IgG4‐RD) of the biliary tree and pancreas is difficult to distinguish from sclerosing cholangitis and biliary/pancreatic malignancies (CA). An accurate noninvasive test for diagnosis and monitoring of disease activity is lacking. We demonstrate that dominant IgG4 + B‐cell receptor (BCR) clones determined by next‐generation sequencing accurately distinguish patients with IgG4‐associated cholangitis/autoimmune pancreatitis (n = 34) from those with primary sclerosing cholangitis (n = 17) and CA (n = 17). A novel, more affordable, and widely applicable quantitative polymerase chain reaction (qPCR) protocol analyzing the IgG4/IgG RNA ratio in blood also achieves excellent diagnostic accuracy (n = 125). Moreover, this qPCR test performed better than serum IgG4 levels in sensitivity (94% vs. 86%) and specificity (99% vs. 73%) and correlates with treatment response (n = 20). Conclusions : IgG4 + BCR clones and IgG4/IgG RNA ratio markedly improve delineation, early diagnosis, and monitoring of IgG4‐RD of the biliary tree and pancreas. (H epatology 2016;64:501‐507)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890 · cited 17×
“4 g/L (group B)((7,8)); and (3) patient had suspicion of pancreatic disease and/or strictures of bile ducts together with two or more of the following: elevated sIgG4 levels, suggestive pancreatic imaging findings, other organ involvement, and/or bile duct biopsy with >10 IgG4(1) B cells/high-power field in combinatio…”
BackgroundMethodInfluentialExposure to occupational antigens might predispose to IgG4-related disease
de Buy Wenniger, L. J. M., Culver, E. L., & Beuers, U. (2014) · Hepatology · doi:10.1002/hep.26999 · Cited by 124
Self-citation
Cited by
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Primary sclerosing cholangitis
Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W., & Hudson, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30300-3 · Cited by 462
Self-citationAdvances in the diagnosis and management of IgG4 related disease
Lanzillotta, M., Mancuso, G., & Della-Torre, E. (2020) · BMJ · doi:10.1136/bmj.m1067 · Cited by 360
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Kendall, T., Verheij, J., Gaudio, E., Evert, M., Guido, M., Goeppert, B., & Carpino, G. (2019) · Liver International · doi:10.1111/liv.14093 · Cited by 350
Self-citationSurgery for cholangiocarcinoma
Cillo, U., Fondevila, C., Donadon, M., Gringeri, E., Mocchegiani, F., Schlitt, H. J., Ijzermans, J. N. M., Vivarelli, M., Zieniewicz, K., Olde Damink, S. W. M., et al. (2019) · Liver International · doi:10.1111/liv.14089 · Cited by 335
The ascending pathophysiology of cholestatic liver disease
Jansen, P. L. M., Ghallab, A., Vartak, N., Reif, R., Schaap, F. G., Hampe, J., & Hengstler, J. G. (2017) · Hepatology · doi:10.1002/hep.28965 · Cited by 301
“isolated IgG4(1) B-cell receptor clones from plasma of patients with IgG4 cholangitis.((67)) Perhaps the isolation of antimitochondrial antibody–positive or perinuclear antineutrophil cytoplasmic antibody–positive B-cell receptor clones could be explored to detect early PBC or PSC.”
BackgroundChapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations
Löhr, J., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J. B., Buttgereit, F., Capurso, G., Culver, E. L., de‐Madaria, E., Della‐Torre, E., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620934911 · Cited by 252
“Moderate elevation of serum IgG4 is also described in about 10% of patients with PSC, cholangiocarcinoma, pancreatitis, and pancreatic carcinoma.(3,6,9) The blood IgG4/IgG RNA ratio, as determined using qPCR, showed excellent accuracy for the diagnosis of IRC (in comparison to PSC and cholangio-/pancreatic carcinoma)…”
BackgroundMethodSelf-citationAnnexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease
Hubers, L. M., Vos, H., Schuurman, A. R., Erken, R., Oude Elferink, R. P., Burgering, B., van de Graaf, S. F. J., & Beuers, U. (2018) · Gut · doi:10.1136/gutjnl-2017-314548 · Cited by 189
Self-citationThe Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases
Cargill, T., & Culver, E. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661196 · Cited by 46
“Circulating PBs and activated PD1+ Tfh cells are decreased and clonal B cell expansion is reduced within 12 weeks of prednisolone therapy in adults with IgG4-HPB disease (57, 132, 133).”
BackgroundSelf-citationRole of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection
Herta, T., Kersten, R., Chang, J.-C., Hubers, L., Go, S., Tolenaars, D., Paulusma, C. C., Nathanson, M. H., Elferink, R. O., van de Graaf, S. F. J., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.009 · Cited by 25
Self-citation
Metadata
- Authors
- Doorenspleet, M. E., Hubers, L. M., Culver, E. L., Maillette de Buy Wenniger, L. J., Klarenbeek, P. L., Chapman, R. W., Baas, F., van de Graaf, S. F., Verheij, J., van Gulik, T. M., Barnes, E., Beuers, U., & de Vries, N.
- Venue
- Hepatology
- Published
- 2016-06-08
- Volume
- 64
- Issue
- 2
- Pages
- 501-507
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2304710142
- Cited by
- 91
- References
- 3
- FWCI
- 17.76
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.